JHU-2545在PSMA靶向显像中优先保护唾液腺与肾脏
本研究合成2-PMPA前药JHU-2545,在小鼠中比较其向血浆、肾脏、唾液腺与C4-2前列腺癌移植瘤递送2-PMPA的药代动力学,并在大鼠与小鼠中评估JHU-2545预处理对PSMA PET示踪剂摄取的影响。结果显示JHU-2545使唾液腺与肾脏中2-PMPA暴露分别约为肿瘤的3倍与53倍,并将肾脏与唾液腺对[68Ga]Ga-PSMA-11和[18F]F-DCFPyL的摄取最多阻断85%,对肿瘤影响很小。作者认为JHU-2545预处理可能允许更高的PSMA放射性配体治疗累积给药剂量。
要点
- JHU-2545使2-PMPA在唾液腺与肾脏的暴露分别约为肿瘤的3倍与53倍。
- JHU-2545将肾脏与唾液腺对PSMA PET示踪剂摄取最多阻断85%,对肿瘤影响很小。
- 作者认为JHU-2545预处理可能允许更高的PSMA放射性配体治疗累积剂量。
核心结论
- JHU-2545预处理可能允许更高的PSMA放射性配体治疗累积给药剂量,并可能改善安全性与疗效。
研究设计与样本
- 合成2-PMPA的三(异丙氧羰基氧甲基)(TrisPOC)前药JHU-2545以增强2-PMPA向非恶性组织的递送。
- 在小鼠中进行药代动力学实验,比较JHU-2545介导的2-PMPA向血浆、肾脏、唾液腺与C4-2前列腺癌移植瘤的递送。
- 在大鼠与小鼠中进行显像研究,测定有与无JHU-2545预处理时肾脏、唾液腺与前列腺癌移植瘤对PSMA PET示踪剂的摄取。
主要发现
- JHU-2545使2-PMPA在啮齿类动物唾液腺(18.0 ± 0.97 h*nmol/g)与肾脏(359 ± 4.16 h*nmol/g)的暴露分别约为前列腺癌移植瘤(6.79 ± 0.19 h*nmol/g)的3倍与53倍。
- JHU-2545将啮齿类动物肾脏与唾液腺对[68Ga]Ga-PSMA-11和[18F]F-DCFPyL的摄取最多阻断85%,对肿瘤影响很小。
关键数值与推荐
- 唾液腺中2-PMPA暴露为18.0 ± 0.97 h*nmol/g,肾脏为359 ± 4.16 h*nmol/g,前列腺癌移植瘤为6.79 ± 0.19 h*nmol/g。
- JHU-2545将肾脏与唾液腺对[68Ga]Ga-PSMA-11和[18F]F-DCFPyL的摄取最多阻断85%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage mCRPC and one, [[177Lu]Lu]Lu-PSMA-617, is FDA approved. In addition to tumor upregulation, PSMA is also expressed in kidneys and salivary glands where specific uptake can cause dose-limiting xerostomia and potential for nephrotoxicity. The PSMA inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA) can prevent kidney uptake in mice, but also blocks tumor uptake, precluding its clinical utility. Preferential delivery of 2-PMPA to non-malignant tissues could improve the therapeutic window of PSMA radioligand therapy. METHODS: A tris(isopropoxycarbonyloxymethyl) (TrisPOC) prodrug of 2-PMPA, JHU-2545, was synthesized to enhance 2-PMPA delivery to non-malignant tissues. Mouse pharmacokinetic experiments were conducted to compare JHU-2545-mediated delivery of 2-PMPA to plasma, kidney, salivary glands, and C4-2 prostate tumor xenograft. Imaging studies were conducted in rats and mice to measure uptake of PSMA PET tracers in kidney, salivary glands, and prostate tumor xenografts with and without JHU-2545 pre-treatment. RESULTS: JHU-2545 resulted in approximately 3- and 53-fold greater exposure of 2-PMPA in rodent salivary glands (18.0 ± 0.97 h*nmol/g) and kidneys (359 ± 4.16 h*nmol/g) versus prostate tumor xenograft (6.79 ± 0.19 h*nmol/g). JHU-2545 also blocked rodent kidneys and salivary glands uptake of the PSMA PET tracers [68Ga]Ga-PSMA-11 and [18 F]F-DCFPyL by up to 85% with little effect on tumor. CONCLUSIONS: JHU-2545 pre-treatment may enable greater cumulative administered doses of PSMA radioligand therapy, possibly improving safety and efficacy.
引用
- Nedelcovych MT, Dash RP, Wu Y, et al. JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 39743616. doi:10.1007/s00259-024-07044-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。